Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Mount Sinai is first in New York state to perform new Alzheimer's imaging test in clinical setting

20.06.2012
Innovative technique expected to play a critical role in diagnosis and treatment of disease

The Mount Sinai Medical Center is the first institution in New York State to use in the clinical setting a newly approved imaging technique to detect Alzheimer's disease (AD) in people who are cognitively impaired.

Until now, physicians have been limited in their ability to diagnose AD, guided almost exclusively by a patient's mental and behavioral symptoms and family history. The innovative technique—recently approved by the U.S. Food and Drug Administration (FDA), is not only expected to play a critical role in the diagnosis of AD, but in drug research, and the design of clinical trials leading to a cure.

Under the new procedure, patients are injected with a radioactive agent called florbetapir, which binds to the plaques that are hallmark symptoms of AD. The physician then uses a positron emission tomography (PET) scan to highlight the plaques that are binded to the agent. If a large amount of florbetapir is visualized on the image, the patient may have AD. If no plaques are found, this could eliminate AD as a possible cause of the patient's cognitive impairment.

"Until now, a diagnosis of Alzheimer's disease could only be pathologically confirmed at autopsy," said Samuel Gandy, MD, Professor of Neurology and Psychiatry and Director of the Mount Sinai Center for Cognitive Health and NFL Neurological Center at The Mount Sinai Medical Center. "Coupled with traditional clinical examination, florbetapir is a promising tool in helping confirm the diagnosis of a patient who is dealing with cognitive impairment. While we cannot exclude the presence of very low levels of amyloid, a negative test means that a memory problem is likely due to some other cause."

Alzheimer's disease is one of several possible causes of cognitive decline. Symptoms may overlap with other causes of cognitive impairment including memory loss; loss in visuospatial ability and executive function; and behavioral and language difficulties. The imaging technique will be used as an adjunctive tool with traditional methods of diagnosis to help determine if these symptoms are related to AD and if not, eliminate it as a likely cause of them.

"The approval of this agent by the FDA for PET imaging of the brain, already available at The Mount Sinai Medical Center, marks a significant advance in the evaluation of patients suspected of having or being at risk for Alzheimer's Disease," said Josef Machac, MD, Director of Nuclear Medicine and Professor of Radiology at The Mount Sinai Medical Center. "The principal value of this procedure at this time is in excluding beta-amyloid and Alzheimer's disease as cause for memory or cognitive decline. This can help in patient management, and in clinical trials of investigational therapies to find more effective treatment."

Florbetapir is anticipated to be most useful in the research setting, providing scientists with a tool for measuring the efficacy of certain drugs on patients who present with cognitive impairment or AD. The scan will help determine which patients are appropriate for which trials, which drugs are effective and for what duration, and provide a better assessment for disease progression.

"From a research perspective, this imaging technique is a major advance that will propel us forward in designing clinical trials and determining drug efficacy for this debilitating disease," said Dr. Gandy. "I look forward to using it both in my clinical practice to help diagnose my patients, and in my research on the quest for a cure for Alzheimer's disease."

AD is an incurable, progressive neurodegenerative disease affecting more than five million people worldwide, and is the leading cause of dementia in the elderly. Presently, there is no cure for Alzheimer's disease.

Florbetapir is marketed as Amyvid™ by Eli Lilly and Company and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly.

About The Mount Sinai Medical Center

The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Mount Sinai School of Medicine. Established in 1968, Mount Sinai School of Medicine is one of the leading medical schools in the United States. The Medical School is noted for innovation in education, biomedical research, clinical care delivery, and local and global community service. It has more than 3,400 faculty in 32 departments and 14 research institutes, and ranks among the top 20 medical schools both in National Institutes of Health (NIH) funding and by U.S. News & World Report.

The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation's oldest, largest and most-respected voluntary hospitals. In 2011, U.S. News & World Report ranked The Mount Sinai Hospital 16th on its elite Honor Roll of the nation's top hospitals based on reputation, safety, and other patient-care factors. Of the top 20 hospitals in the United States, Mount Sinai is one of 12 integrated academic medical centers whose medical school ranks among the top 20 in NIH funding and U.S. News & World Report and whose hospital is on the U.S. News & World Report Honor Roll. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 560,000 outpatient visits took place.

Mount Sinai Press Office | EurekAlert!
Further information:
http://www.mssm.edu

More articles from Health and Medicine:

nachricht NIST scientists discover how to switch liver cancer cell growth from 2-D to 3-D structures
17.11.2017 | National Institute of Standards and Technology (NIST)

nachricht High speed video recording precisely measures blood cell velocity
15.11.2017 | ITMO University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A “cosmic snake” reveals the structure of remote galaxies

The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.

Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...

Im Focus: Visual intelligence is not the same as IQ

Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.

That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...

Im Focus: Novel Nano-CT device creates high-resolution 3D-X-rays of tiny velvet worm legs

Computer Tomography (CT) is a standard procedure in hospitals, but so far, the technology has not been suitable for imaging extremely small objects. In PNAS, a team from the Technical University of Munich (TUM) describes a Nano-CT device that creates three-dimensional x-ray images at resolutions up to 100 nanometers. The first test application: Together with colleagues from the University of Kassel and Helmholtz-Zentrum Geesthacht the researchers analyzed the locomotory system of a velvet worm.

During a CT analysis, the object under investigation is x-rayed and a detector measures the respective amount of radiation absorbed from various angles....

Im Focus: Researchers Develop Data Bus for Quantum Computer

The quantum world is fragile; error correction codes are needed to protect the information stored in a quantum object from the deteriorating effects of noise. Quantum physicists in Innsbruck have developed a protocol to pass quantum information between differently encoded building blocks of a future quantum computer, such as processors and memories. Scientists may use this protocol in the future to build a data bus for quantum computers. The researchers have published their work in the journal Nature Communications.

Future quantum computers will be able to solve problems where conventional computers fail today. We are still far away from any large-scale implementation,...

Im Focus: Wrinkles give heat a jolt in pillared graphene

Rice University researchers test 3-D carbon nanostructures' thermal transport abilities

Pillared graphene would transfer heat better if the theoretical material had a few asymmetric junctions that caused wrinkles, according to Rice University...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Ecology Across Borders: International conference brings together 1,500 ecologists

15.11.2017 | Event News

Road into laboratory: Users discuss biaxial fatigue-testing for car and truck wheel

15.11.2017 | Event News

#Berlin5GWeek: The right network for Industry 4.0

30.10.2017 | Event News

 
Latest News

NASA detects solar flare pulses at Sun and Earth

17.11.2017 | Physics and Astronomy

NIST scientists discover how to switch liver cancer cell growth from 2-D to 3-D structures

17.11.2017 | Health and Medicine

The importance of biodiversity in forests could increase due to climate change

17.11.2017 | Studies and Analyses

VideoLinks
B2B-VideoLinks
More VideoLinks >>>